Sun Pharmaceutical Industries announced that the US FDA conducted an inspection at the Company`s Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI). Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis. �ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to severe plaque psoriasis,� said Kirti Ganorkar, Managing Director, Sun Pharma. �We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.�ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.Powered by Capital Market - Live News

Net profit of Sun Pharmaceutical Industries rose 2.56% to Rs 3117.95 crore in the quarter ended September 2025 as against Rs 3040.16 crore during the previous quarter ended September 2024. Sales rose 8.60% to Rs 14405.22 crore in the quarter ended September 2025 as against Rs 13264.22 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales14405.2213264.22 9 OPM %31.4329.70 - PBDT4897.114223.79 16 PBT4167.613597.88 16 NP3117.953040.16 3 Powered by Capital Market - Live News

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live News

Net profit of Sun Pharmaceutical Industries declined 19.64% to Rs 2278.63 crore in the quarter ended June 2025 as against Rs 2835.62 crore during the previous quarter ended June 2024. Sales rose 10.07% to Rs 13786.07 crore in the quarter ended June 2025 as against Rs 12524.51 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales13786.0712524.51 10 OPM %31.2028.80 - PBDT4691.324078.63 15 PBT3990.773423.50 17 NP2278.632835.62 -20 Powered by Capital Market - Live News